For Research Purposes Only — Not for Human Consumption
All products on this website are supplied strictly for laboratory and research purposes only. They are not medicines, foods, or supplements, and are not intended for human consumption, human or veterinary use, or to diagnose, treat, cure, or prevent any disease.
Retatrutide
A triple receptor agonist of GLP-1, GIP and glucagon studied for its role in metabolic and weight management research.
30mg Retatrutide pre-filled disposable pen (single-use). Includes 10 single-use needles and 10 alcohol wipes.
Note: This is a reconstitution kit — you are responsible for measuring and preparing the product yourself.
Research Use Only: This product is supplied strictly for laboratory and research purposes and is not intended for human consumption, human or veterinary use, or to diagnose, treat, cure, or prevent any disease.
Product Information
Retatrutide is an investigational triple agonist peptide acting on GLP-1, GIP and glucagon receptors, studied extensively in metabolic research.
Scientific Overview
Retatrutide (also known as LY3437943) is a synthetic 39-amino-acid peptide engineered to simultaneously act as an agonist at three key metabolic receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. This triple-agonist mechanism distinguishes it from single (GLP-1 only) or dual (GLP-1/GIP) incretin agonists and is of significant interest in research exploring appetite regulation, energy expenditure, and glucose homeostasis. Its extended half-life — supporting once-weekly dosing protocols in study settings — is attributed to fatty acid acylation and amino acid substitutions that slow enzymatic degradation and reduce renal clearance.
How It Works
Retatrutide exerts its studied effects through simultaneous activation of three receptor pathways. GLP-1 receptor agonism is associated with delayed gastric emptying, increased satiety signalling to the brain, and reduced appetite. GIP receptor agonism is studied for its influence on insulin secretion in response to meals and on adipose tissue metabolism. Glucagon receptor agonism is associated with increased energy expenditure, the breakdown of stored fat (lipolysis), and hepatic glucose output. The combined engagement of all three pathways is researched for its potential to produce greater reductions in body weight and improvements in metabolic markers than targeting any single receptor alone.
Research & References
The information on this page is supported by peer-reviewed clinical research and published trial data.
Frequently Asked Questions
It is a triple agonist studied for activity at GLP-1, GIP and glucagon receptors.
Variant Comparison
Compare the available formats side-by-side to find the right option for your research needs.
| Compare | Selected 30mg Disposable Pen £100 | 60mg Disposable Pen £150 | 30mg Retatrutide Vial Kit £90 |
|---|---|---|---|
| Format | — | — | — |
| Total Retatrutide | — | — | — |
| Price per mg | — | — | — |
| Single-use needles | — | — | — |
| Alcohol wipes | — | — | — |
| Bacteriostatic water | 3ml | ||
| Pre-mixed & ready | |||
| Self-measurement required |
Peptide Comparison
See how Retatrutide compares to related peptides in the same category.
| Compare | Selected Retatrutide £189.00 |  Tirzepatide £159.00 |
|---|---|---|
| What it does | A triple receptor agonist of GLP-1, GIP and glucagon studied for its role in metabolic and weight management research. | A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, studied for its synergistic metabolic effects. |
| Category | GLP-1 | GLP-1 |
| Molecular mass | ≈4731 Da | ≈4814 Da |
| Purity | ≥99% | ≥99% |
| Sequence length | 39 aa | 39 aa |
Knowledge Articles
Related Products
For Research Purposes Only — Not for Human Consumption
All products on this website are supplied strictly for laboratory and research purposes only. They are not medicines, foods, or supplements, and are not intended for human consumption, human or veterinary use, or to diagnose, treat, cure, or prevent any disease.